Hofseth BioCare Publishes Groundbreaking Omega-3 Clinical Trial Results

OmeGo full spectrum omega supplement outperforms leading brand in boosting Omega-3 Index and reducing inflammation

Apr. 14, 2026 at 9:04am

Got story updates? Submit your updates here. ›

An extreme macro X-ray photograph showing the intricate molecular structure of omega-3 fatty acids, with glowing ghostly lines and shapes against a dark background, conceptually illustrating the scientific insights behind the clinical trial results.A revealing X-ray view of the complex molecular structure behind omega-3's proven health benefits.Los Angeles Today

Hofseth BioCare ASA (HBC), a Norwegian consumer and pet health company, has published the results of a head-to-head clinical trial showing that its patented OmeGo full spectrum omega supplement increased the Omega-3 Index by over 70% after 14 weeks, significantly outperforming a leading omega-3 supplement brand. The trial also found that OmeGo was more effective at reducing key inflammatory markers linked to various health issues.

Why it matters

These findings challenge the prevailing market assumption that higher-dose concentrated fish oils deliver greater health benefits. The study suggests that HBC's whole food-based OmeGo formula, which contains less EPA and DHA than the comparator supplement, is more bioavailable and better replicates the health benefits associated with regularly eating fish.

The details

The clinical trial showed that OmeGo increased the Omega-3 Index (O3I) - a measure of EPA and DHA levels in red blood cells - by over 70% after 14 weeks. This was markedly more effective than the leading omega-3 supplement brand used in the study. OmeGo was also found to be more successful at reducing key inflammatory markers like hsCRP, TNFa and IL-6, which are closely linked to the development of various health conditions.

  • The clinical trial results were published on April 14, 2026.

The players

Hofseth BioCare ASA (HBC)

A Norwegian consumer and pet health company that upcycles side streams from the salmon industry to produce ingredients like ProGo, OmeGo, and CalGo for human and animal health.

OmeGo

HBC's patented full spectrum omega supplement that was shown to be more effective than a leading omega-3 brand at increasing the Omega-3 Index and reducing inflammation.

Got photos? Submit your photos here. ›

What they’re saying

“These clinical trial results directly challenge the prevailing market assumption that higher-dose concentrated fish oils deliver greater health benefits. Our study suggests that HBC's whole food-based OmeGo formula, which contains less EPA and DHA than the comparator supplement, is more bioavailable and better replicates the health benefits associated with regularly eating fish.”

— James Berger, CCO at Hofseth BioCare ASA

What’s next

HBC plans to use these findings to further promote the benefits of its OmeGo full spectrum omega supplement and challenge the dominance of concentrated fish oil products in the nutraceuticals market.

The takeaway

This study represents a potential paradigm shift in how the omega-3 supplement industry views potency and bioavailability, suggesting that a whole food-based formula like OmeGo may be more effective than higher-dose concentrated fish oils at delivering the health benefits associated with omega-3 fatty acids.